News

  1. Elizabeth Hickman To Succeed Tim Scott As AustinPx CEO 3/5/2024

    AustinPx, developers of the next generation amorphous dispersion platform, KinetiSol™ Technology, and a contract development and manufacturing organization (CDMO), today announced that Elizabeth Hickman, chief business officer, will succeed Tim Scott in January 2025 as president and CEO of AustinPx. Scott has led the company’s new direction as a CDMO since 2022, successfully positioning the company’s leadership as an oral drug delivery dosage form development CDMO. Scott will stay on as executive chair following the transition and Hickman will be named to the Board of Directors.

  2. Allegheny Performance Plastics® Launches Into Healthcare Sector 3/5/2024

    To meet the growing needs of the healthcare industry, Allegheny Performance Plastics is proud to announce the addition of clean and white room environments, including a dedicated automated work cell to be completed later this year.

  3. Adare Pharma Solutions To Expand Packaging & Warehousing Capabilities In Europe 3/5/2024

    Adare Pharma Solutions, a global technology-driven CDMO focused on oral dosage forms, today announced that work has begun to add packaging capabilities and further warehousing capacity at its Pessano facility in Milan, Italy.

  4. SGD Pharma Awarded 2024 Gold EcoVadis Rating In Recognition Of Its Commitment To Sustainability 2/26/2024

    SGD Pharma, a global leader in glass pharmaceutical packaging, has achieved a gold medal in EcoVadis’ 2024 sustainability ratings. Building upon previous years, SGD Pharma’s score of 77 puts the business in the 98th percentile for manufacturers of glass and glass products. EcoVadis, the world’s most trusted provider of sustainability ratings, assesses more than 125,000 companies across four main areas: Environment, Labor and Human Rights, Sustainable Procurement and Ethics.

  5. SGD Pharma introduces Its New Range Of Type I tubular Vials Featuring Corning's Velocity® Vial Coating Technology 2/9/2024

    SGD Pharma, global market leader in molded glass primary packaging solutions for the pharmaceutical industry, announces its new range of high-quality Type I injectable vials in tubular glass with the added external low-friction coating developed by Corning thanks to an exclusive co-development partnership. SGD Pharma’s vial-converting expertise is combined with Corning’s® proprietary glass-coating technology to improve pharmaceutical filling-line productivity and speed the global delivery of injectable treatments.

  6. Novo Holdings To Acquire CDMO Catalent Pharma Solutions For $16.5 Billion 2/5/2024

    Catalent, Inc. (NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings, a holding and investment company that is responsible for managing the assets and wealth of the Novo Nordisk Foundation, today announced that they have entered into a merger agreement under which Novo Holdings will acquire Catalent in an all-cash transaction that values Catalent at $16.5 billion on an enterprise value basis.

  7. SGD Pharma Optimizes Global Fill And Finish Operations With The Introduction Of Its New Range Of Type I Tubular Vials Featuring Corning's Velocity® Vial Coating Technology For Enhanced Product Quality And Patient Safety 2/5/2024

    SGD Pharma, global market leader in molded glass primary packaging solutions for the pharmaceutical industry, announces its new range of high-quality Type I injectable vials in tubular glass with the added external low-friction coating developed by Corning thanks to an exclusive co-development partnership. SGD Pharma’s vial-converting expertise is combined with Corning’s® proprietary glass-coating technology to improve pharmaceutical filling-line productivity and speed the global delivery of injectable treatments.

  8. AustinPx Partners With Microsize On KinetiSol® Technology 1/31/2024

    AustinPx, a contract development and manufacturing organization (CDMO) specializing in bioavailability enhancement of orally delivered small molecule drug candidates, and Microsize, a leading active pharmaceutical ingredient enhancement CDMO, today announced the strategic partnership to accelerate the commercial application of AustinPx’s KinetiSol® Technology platform. The collaboration will enable AustinPx’s clients to manufacture their late-phase clinical and commercial KinetiSol drug product intermediate at Microsize’s purpose built, FDA-inspected facility.

  9. Rob Albert Appointed Chief Executive Officer Of B. Braun Of America Inc. 1/26/2024

    The Board of Directors of B. Braun of America Inc. (“B. Braun of America”) announced today that they have appointed Rob Albert as Chief Executive Officer of B. Braun of America, succeeding Jean-Claude Dubacher who is taking on global management responsibilities, while remaining Chairman of the Board of B. Braun of America. Albert’s appointment will be effective April 1, 2024.

  10. INTEPRHEX Puts Hot-Topic Science In 2024 Event Registration Now Open | Event Program Now Online 1/22/2024

    The reimagined INTERPHEX Conference is designed to bring attendees together to solve their business challenges and to understand the science that is shaping their industries.